The Effect of Induction Chemotherapy Using Docetaxel, Cisplatin, and Fluorouracil on Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose The purpose of this study was to compare the survival of patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) undergoing concurrent chemoradiotherapy (CRT) alone with that of patients undergoing induction chemotherapy (IC) using docetaxel, cisplatin, and 5-fluorouracil (TPF) followed by CRT. Materials and Methods A search of the PubMed, EMBASE, and Cochrane Library databases was performed in April 2015 and abstracts from the American Society of Clinical Oncology meetings (2008-2014) were reviewed. Summaries of the results were pooled using a fixed-effect model, and the risk of bias was evaluated using the Cochrane tool. Results A total of six relevant trials comprising 1,280 patients were identified. There was no statistically significant overall survival (OS) advantage for TPF prior to CRT (TPF/CRT) over CRT alone (hazard ratio [HR] 0.92; 95% confidence interval [CI], 0.79 to 1.09; p=0.339). Progression- free survival (PFS) was significantly longer in the TPF/CRT arms (HR, 0.82; 95% CI, 0.70 to 0.95; p=0.009). Patients with non-oropharyngeal LA-HNSCC obtained the greatest OS and PFS benefits from TPF (HR, 0.68; 95% CI, 0.47 to 0.99; p=0.043 and HR, 0.67; 95% CI, 0.48 to 0.94; p=0.022, respectively). The complete response rate was significantly increased (risk ratio [RR], 1.34; 95% CI, 1.14 to 1.56; p < 0.001), and the distant metastasis rate tended to decrease (RR, 0.65; 95% CI, 0.40 to 1.04; p=0.071) in the TPF/CRT arms. Conclusion IC with TPF followed by CRT is not superior to CRT alone for OS. However, PFS and the complete response rate were significantly improved in the TPF/CRT arms. TPF/CRT for patients with nonoropharyngeal LA-HNSCC provided clear survival advantages.
Abstract
Purpose The purpose of this study was to compare the survival of patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) undergoing concurrent chemoradiotherapy (CRT) alone with that of patients undergoing induction chemotherapy (IC) using docetaxel, cisplatin, and 5-fluorouracil (TPF) followed by CRT. Materials and Methods A search of the PubMed, EMBASE, and Cochrane Library databases was performed in April 2015 and abstracts from the American Society of Clinical Oncology meetings (2008-2014) were reviewed. Summaries of the results were pooled using a fixed-effect model, and the risk of bias was evaluated using the Cochrane tool. Results A total of six relevant trials comprising 1,280 patients were identified. There was no statistically significant overall survival (OS) advantage for TPF prior to CRT (TPF/CRT) over CRT alone (hazard ratio [HR] 0.92; 95% confidence interval [CI], 0.79 to 1.09; p=0.339). Progression- free survival (PFS) was significantly longer in the TPF/CRT arms (HR, 0.82; 95% CI, 0.70 to 0.95; p=0.009). Patients with non-oropharyngeal LA-HNSCC obtained the greatest OS and PFS benefits from TPF (HR, 0.68; 95% CI, 0.47 to 0.99; p=0.043 and HR, 0.67; 95% CI, 0.48 to 0.94; p=0.022, respectively). The complete response rate was significantly increased (risk ratio [RR], 1.34; 95% CI, 1.14 to 1.56; p < 0.001), and the distant metastasis rate tended to decrease (RR, 0.65; 95% CI, 0.40 to 1.04; p=0.071) in the TPF/CRT arms. Conclusion IC with TPF followed by CRT is not superior to CRT alone for OS. However, PFS and the complete response rate were significantly improved in the TPF/CRT arms. TPF/CRT for patients with nonoropharyngeal LA-HNSCC provided clear survival advantages.
참고문헌 (24)
- Pignon JP, "Chemotherapy added to locoregional treatment for head and neck squamouscell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer", Lancet, 355, pp.949~955 (2000)
- Haddad RI, "Recent advances in head and neck cancer", N Engl J Med, 359, pp.1143~1154 (2008)
- Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer, "The Department of Veterans Affairs Laryngeal Cancer Study Group", N Engl J Med, 324, pp.1685~1690 (1991)
- Ferlay J, "Estimates of cancer incidence and mortality in Europe in 2008", Eur J Cancer, 46, pp.765~781 (2010)
- Hitt R, "Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer", J Clin Oncol, 23, pp.8636~8645 (2005)
- Posner MR, "Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer", N Engl J Med, 357, pp.1705~1715 (2007)
- Vermorken JB, "Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer", N Engl J Med, 357, pp.1695~1704 (2007)
- Blanchard P, "Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers : an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group", J Clin Oncol, 31, pp.2854~2860 (2013)
- Cohen EE, "Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer", J Clin Oncol, 32, pp.2735~2743 (2014)
- Haddad R, "Induction chemotherapy followed by concurrent chemoradiotherapy(sequential chemoradiotherapy)versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer(PARADIGM) : a randomised phase 3trial", Lancet Oncol, 14, pp.257~264 (2013)
- Hitt R, "A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer", Ann Oncol, 25, pp.216~225 (2014)
- Faivre S, "Induction chemotherapy challenges for head and neck cancer", Lancet Oncol, 14, pp.188~189 (2013)
- Ghi MG, "Concomitant chemoradiation (CRT) or cetuximab", RT (CET, cisplatin, pp.5-fluorouracil (TPF) followed by CRT or CET, RT in patients with locally advanced squamous cell carcinoma of head and neck (LASCCHN). A randomized phase III factorial study (NCT01086826)[DOI]
- Zhang L, "Induction chemotherapy with concurrent chemoradiotherapy versus concurrent chemoradiotherapy for locally advanced squamous cell carcinoma of head and neck : a meta-analysis", Sci Rep, 5, pp.10798~ (2015)
- Takacsi-Nagy Z, "Docetaxel, cisplatin and 5-fluorouracil induction chemotherapy followed by chemoradiotherapy or chemoradiotherapy alone in stage III-IV unresectable head and neck cancer : results of a randomized phase II study", Strahlenther Onkol, 191, pp.635~641 (2015)
- Higgins JP, "Cochrane handbook for systematic reviews of interventions" (2008), John Wiley & Sons
- DerSimonian R, "Meta-analysis in clinical trials", Control Clin Trials, 7, pp.177~188 (1986)
- Higgins JP, "Measuring inconsistency in meta-analyses", BMJ, 327, pp.557~560 (2003)
- Begg CB, "Operating characteristics of a rank correlation test for publication bias", Biometrics, 50, pp.1088~1101 (1994)
- Egger M, "Bias in meta-analysis detected by a simple, graphical test", BMJ, 315, pp.629~634 (1997)
- Therasse P, "New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada", J Natl Cancer Inst, 92, pp.205~216 (2000)
- Paccagnella A, "Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil(TPF)followed by concomitant chemoradiotherapy in locally advanced head and neck cancer : a phase II randomized study", Ann Oncol, 21, pp.1515~1522 (2010)
- Das LC, "Comparison of outcomes of locoregionally advanced oropharyngeal and non-oropharyngeal squamous cell carcinoma over two decades", Ann Oncol, 26, pp.198~205 (2015)
- Ang KK, "Human papillomavirus and survival of patients with oropharyngeal cancer", N Engl J Med, 363, pp.24~35 (2010)